Halozyme Therapeutics | HALO - Interest Expense On Debt


Halozyme Therapeutics reported $4.91M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amarin USD 3K 5K Dec/2024
Amgen USD 653M 32M Dec/2025
Baxter International USD 58M 14M Sep/2025
Cara Therapeutics 43.75M 4.8M Jun/2025
Cytokinetics USD 30.33M 4.01M Dec/2025
DBV Technologies USD 461K 323.71K Mar/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Intrexon USD 2K 5K Jun/2024
Ionis Pharmaceuticals USD 18M 0 Dec/2025
MannKind USD 13.87M 6.54M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 6.02M 420K Sep/2024
Pfizer USD 711M 59M Dec/2025
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
United Therapeutics USD 3.1M 100K Dec/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025